Third Rock Ventures’ Post

Discover how to engineer and analyze CAR-T cell signaling and activation using cutting-edge tools in our upcoming webinar. Learn from experts about innovative non-viral editing and analytical platforms that enhance CAR-T cell therapy efficiency. #CARTTherapy #GeneEditing #CancerResearch https://lnkd.in/gaQq5EVi

ABECMA A CAR-T Cell therapy, uses patients' T cells to create a personalized version of their own immune system, potentially improving the chances of anti-tumour response long after treatment administration. Here is a summary

⏰ Save The Date - 27th June ⏰ Join our upcoming webinar featuring a panel discussion on methods of streamlining the CAR-T workflow. As CAR-T cell therapy continues to advance it's important to address the challenges that come with it. One key issue is the manufacturing process, which can be costly and time-consuming. That's why efforts to create a more efficient CAR-T cell therapy manufacturing process are crucial. Join this webinar to learn more about the analytical tools that are contributing to these advancements! #celltherapy #CART

https://lnkd.in/eHPd8U6z We agree with this observation but why stop there. A full HLA match (i.e., autologous) approach could be even better. Let’s remember that all 8 approved oncology cell therapies approved to date are autologous - maybe there’s a reason for that. #Alloplex #celltherapies #SUPLEXA #SUPLEXAtherapy #oncologyresearch #cancerresearch #immunotherapy #autologoustherapy #AlloplexBiotherapeutics

🔍 Join our upcoming webinar to explore the latest advancements in CAR-T cell signaling and activation. Gain insights from leading experts on innovative non-viral editing 🧬 and analytical platforms that are revolutionizing the efficiency of CAR-T cell therapy. 🌟

Today we’re sharing first disclosure data from a Phase 1 study of our GPRC5D-targeted cell therapy at #EHA2024. This research represents one of several modalities we’re exploring for the treatment of patients with relapsed/refractory multiple myeloma, with the goal of providing an option for every patient. Learn more about our cutting-edge research in cell therapy: https://bit.ly/3KHP8Uf

We don’t want your blood (samples). We just want you to be able to analyze them with #scRNA-seq—without stressing about your schedule. That’s why we developed a first-of-its-kind protocol to fix whole blood for downstream single cell profiling. Check out our poster from #AACR24 to see what we learned about multiple myeloma by analyzing fixed blood from patients treated with #CART cell therapy: https://bit.ly/4aiko6H

This September, the spotlight's on #BloodCancer. Explore the cutting-edge journey of Dr. Mohamed Kharfan-Dabaja with CAR-T cell therapy. Discover hope in every breakthrough! Read more here: https://buff.ly/3Ldpwzb #CancerResearch #InnovationInAction #bloodcancerawarenessmonth

Did you know Cytotherapy has a bi-monthly newsletter? Our latest edition covering March and April looks at Vδ2 T Cells, Chronic Illness, and Cell Therapy Investing. Read the full newsletter here: https://lnkd.in/gA86eb-N #Cytotherapy

The challenge of enhancing the effectiveness and durability of engineered lymphocyte therapies is one of the key issues in the field of #lymphocyte engineering and cell therapy. The topic will be discussed in detail by top experts – Michel Sadelain, Univ.-Prof. Dr. med. Marion Subklewe and Jennifer Brogdon during the 1st session of #ICLE2025 – “Real-world experience, novel clinical approaches and combination therapies.” The session will aim to explore the potential synergy between engineered lymphocytes and other treatment modalities. Dive into the program to find out what else to expect: https://bit.ly/4bK8Gm2 #lymphocytes #lymphocytesengineering #CARTcells